Tacrolimus for the Management of Delayed Onset and Treatment-Refractory Immune-Related Hepatitis.
ACG Case Rep J
; 10(4): e01007, 2023 Apr.
Article
in En
| MEDLINE
| ID: mdl-37091207
ABSTRACT
Immune checkpoint inhibitors, such as pembrolizumab, are effective in the management of metastatic malignancies, such as melanoma, and are associated with a spectrum of immune-related organ toxicities, including immune-related hepatitis (ir-hepatitis). The clinical presentation of ir-hepatitis varies in onset and severity, and management involves immunosuppression with corticosteroids and mycophenolate mofetil as first and second-line agents. Several agents have been proposed as third-line options for treatment-refractory disease. We report the successful use of tacrolimus for delayed onset and treatment-refractory ir-hepatitis secondary to pembrolizumab.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
ACG Case Rep J
Year:
2023
Document type:
Article
Affiliation country: